Knee Osteoarthritis
Conditions
Keywords
viscosupplementation
Brief summary
Knee osteoarthritis is a frequent condition whose prevalence is estimated at 7.6% of the French population aged 40 to 75, or approximately 2 million individuals . Viscosupplementation (VS) is a symptomatic treatment of knee osteoarthritis recommended by a large number of learned societies. It consists of the intra-articular injection (IA) of hyaluronic acid (HA), to reduce knee pain by restoring normal joint homeostasis impaired by endogenous HA deficiency. The IA administration of HA can be performed using 2 protocols: repeated weekly injections (3, sometimes 5 injections) and single injections. To date and there is no argument to favor either protocol. Regardless of the formula used, the safety of HA is excellent (RR of adverse reaction versus saline = 1.01, 95% CI 0.96-1.07, P = 0.6). The indication for viscosupplementation is the symptomatic treatment of mild to moderate knee osteoarthritis after failure and / or intolerance of analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs). In this indication, after HA injection the responder rate is in the order of 70% to 75% at 6 months and approximately 50% at 12 months. However, the predictors of the duration of effectiveness of SV are still unknown. The objective of the study is to research the factors influencing the duration of the effectiveness of SV, under real life conditions.
Interventions
OTHERnone intervention
none intervention
Sponsors
Hopital Nord Franche-Comte
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All adult outpatients, of both sexes, regardless of age, with a doctor-accepted diagnosis of knee OA and who have been treated with SV within the past 3 years
Exclusion criteria
* Patients who have not been treated with SV in the past 3 years. * Patients who have been treated with VS for an indication other than osteoarthritis of the knee. * Patients in whom the assessment could not be performed reliably
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Investigate the factors influencing the duration of the effectiveness of SV, under real-life conditions | At inclusion | Duration (in weeks) during which the patient was satisfied with the treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Research for predictive factors will be carried out on the duration of satisfaction | At inclusion | Research for predictive factors will be carried out on the duration of satisfaction |
Countries
France
Outcome results
None listed